Company Overview
Snapshot
Founded in July 2016, TriSol Medical operates with 11–50 employees and has raised $31.43M across four funding rounds from three investors. The company recently announced positive results from its US Early Feasibility Study of its transcatheter tricuspid valve replacement system in January 2026.
Business overview
TriSol Medical is a clinical-stage medical device company focused on developing a best-in-class transcatheter tricuspid replacement valve. Its core technology is a transcatheter tricuspid valve replacement device, constructed from a nitinol frame with a specially designed dome-shaped leaflet, aimed at eliminating Tricuspid Regurgitation while preserving Right Ventricle function. The company serves the healthcare industry, specifically targeting providers and patients with severe Tricuspid Regurgitation, operating within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics.
Strategic signal
In January 2026, TriSol Medical announced positive results from its US Early Feasibility Study for its transcatheter tricuspid valve replacement system. This milestone indicates significant progress in the clinical validation of their device, signaling to investors and the medical community a strong potential for market entry and addressing an unmet need in cardiology.
Log in to access full profile ›Company Intelligence Q&A
- What is TriSol Medical's primary focus?
- TriSol Medical is focused on developing a best-in-class transcatheter tricuspid replacement valve designed to eliminate Tricuspid Regurgitation while preserving Right Ventricle function.
- When was TriSol Medical founded?
- TriSol Medical was founded in July 2016.
- What was a recent significant development for TriSol Medical?
- In January 2026, TriSol Medical announced positive results from its US Early Feasibility Study of its transcatheter tricuspid valve replacement system.
- Has TriSol Medical achieved successful implants of its device?
- Yes, in August 2023, TriSol announced successful implants of its Transcatheter Tricuspid Valve in the US.
- Which investor participated in TriSol Medical's funding round in July 2023?
- In July 2023, European Innovation Council participated in a funding round for TriSol Medical.